Cardiac Dimensions appoints new CEO and President

Cardiac Dimensions, a privately held medical device company, hired Gregory D. Casciaro as its CEO and President on Dec. 15.

Casciaro was formerly CEO and President of AccessClosure, Inc., an interventional cardiology medical device company that Cardinal Health acquired for $320 million in cash in April 2014.

He has also served as CEO and President of XTENT, Inc., Orquest, Inc. and General Surgical Innovations. All three of those companies were acquired by larger companies, according to a Cardiac Dimensions news release.

Cardiac Dimensions has developed the Carillon Mitral Contour System, a percutaneous mitral annuloplasty implantable device intended to treat functional mitral regurgitation in patients with heart failure. The system has received a CE Mark in Europe, but it is not FDA-approved.

In March, Cardiac Dimensions announced it had received $15.2 million in equity financing from two investment firms: Life Sciences Partners and Aperture Venture Partners. The total amount of financing in the round was $43 million, which the company said it would use to fund a blinded, randomized trial evaluating the Carillon system in patients with functional mitral regurgitation.

Approximately 70 percent of the 20 million people who have heart failure also have functional mitral regurgitation, according to the company.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.